Pulmatrix Net Income from 2010 to 2026
| PULM Stock | USD 2.44 0.02 0.81% |
Net Loss | First Reported 2012-06-30 | Previous Quarter -1.5 M | Current Value -877 K | Quarterly Volatility 3.1 M |
Check Pulmatrix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmatrix's main balance sheet or income statement drivers, such as Interest Expense of 197.6 K, Other Operating Expenses of 19 M or Research Development of 11.1 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.13 or PTB Ratio of 3.11. Pulmatrix financial statements analysis is a perfect complement when working with Pulmatrix Valuation or Volatility modules.
Pulmatrix | Net Income | Build AI portfolio with Pulmatrix Stock |
Evaluating Pulmatrix's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Pulmatrix's fundamental strength.
Latest Pulmatrix's Net Income Growth Pattern
Below is the plot of the Net Income of Pulmatrix over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pulmatrix financial statement analysis. It represents the amount of money remaining after all of Pulmatrix operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pulmatrix's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmatrix's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pulmatrix Net Income Regression Statistics
| Arithmetic Mean | (14,152,374) | |
| Coefficient Of Variation | (66.04) | |
| Mean Deviation | 8,023,722 | |
| Median | (18,056,000) | |
| Standard Deviation | 9,346,407 | |
| Sample Variance | 87.4T | |
| Range | 27.8M | |
| R-Value | (0.25) | |
| Mean Square Error | 87.5T | |
| R-Squared | 0.06 | |
| Significance | 0.34 | |
| Slope | (458,517) | |
| Total Sum of Squares | 1397.7T |
Pulmatrix Net Income History
Other Fundumenentals of Pulmatrix
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pulmatrix Net Income component correlations
About Pulmatrix Financial Statements
Pulmatrix investors utilize fundamental indicators, such as Net Income, to predict how Pulmatrix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -11 M | -11.5 M | |
| Net Loss | -17 M | -17.8 M | |
| Net Loss | (2.36) | (2.47) | |
| Net Income Per E B T | 0.81 | 0.72 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Pulmatrix Correlation against competitors. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.